You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Imatinib mesylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for imatinib mesylate and what is the scope of patent protection?

Imatinib mesylate is the generic ingredient in two branded drugs marketed by Novartis, Amneal Pharms, Apotex, Breckenridge, Chartwell Rx, Dr Reddys, Eugia Pharma, Hikma, Mylan, Natco Pharma Ltd, Qilu Pharm Hainan, Shilpa, Sun Pharm, Teva Pharms Usa, and Zydus Pharms, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-four drug master file entries for imatinib mesylate. Twenty-three suppliers are listed for this compound.

Drug Prices for imatinib mesylate

See drug prices for imatinib mesylate

Recent Clinical Trials for imatinib mesylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Inhibikase Therapeutics, Inc.Phase 1
Sarit AssoulinePhase 3
Ningbo No. 1 HospitalPhase 2

See all imatinib mesylate clinical trials

Medical Subject Heading (MeSH) Categories for imatinib mesylate
Paragraph IV (Patent) Challenges for IMATINIB MESYLATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
GLEEVEC Tablets imatinib mesylate 100 mg and 400 mg 021588 1 2007-03-12

US Patents and Regulatory Information for imatinib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm IMATINIB MESYLATE imatinib mesylate TABLET;ORAL 078340-002 Dec 3, 2015 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Breckenridge IMATINIB MESYLATE imatinib mesylate TABLET;ORAL 205990-002 Feb 8, 2019 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Breckenridge IMATINIB MESYLATE imatinib mesylate TABLET;ORAL 205990-001 Feb 8, 2019 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Natco Pharma Ltd IMATINIB MESYLATE imatinib mesylate TABLET;ORAL 207818-001 Mar 1, 2019 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for imatinib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis GLEEVEC imatinib mesylate CAPSULE;ORAL 021335-002 May 10, 2001 ⤷  Try a Trial ⤷  Try a Trial
Novartis GLEEVEC imatinib mesylate CAPSULE;ORAL 021335-001 May 10, 2001 ⤷  Try a Trial ⤷  Try a Trial
Novartis GLEEVEC imatinib mesylate TABLET;ORAL 021588-002 Apr 18, 2003 ⤷  Try a Trial ⤷  Try a Trial
Novartis GLEEVEC imatinib mesylate CAPSULE;ORAL 021335-002 May 10, 2001 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.